Related Experiment Video

Updated: May 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients

Massimiliano Veroux1, Tiziano Tallarita, Daniela Corona

  • 1Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, Via Santa Sofia 84, 95123 Catania, Italy. veroux@unict.it

Expert Review of Anticancer Therapy
|December 25, 2012
PubMed

Insights

Sirolimus (SRL), an mTOR inhibitor, can be safely taken orally once weekly for advanced cancer. This dosing strategy shows potential for targeted cancer therapy and warrants further clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The mechanistic target of rapamycin (mTOR) pathway regulates critical cellular functions and is a key target in cancer therapy.
  • Sirolimus (SRL), an mTOR inhibitor, has demonstrated immunosuppressive and antiproliferative effects, reducing cancer risk in kidney transplant patients.
  • The efficacy of SRL in advanced cancer patients requires further investigation.

Discussion:

  • This review examines a study on the oral, weekly administration of SRL, alone or with CYP3A4 inhibitors (grapefruit juice, ketoconazole), to achieve therapeutic concentrations.
  • The study assessed the feasibility and pharmacokinetic profile of weekly oral SRL, comparing it to other mTOR inhibitors.
  • The findings support the potential of SRL as an oral targeted therapy for advanced cancers.

Key Insights:

  • Weekly oral administration of sirolimus is feasible for advanced cancer patients.
  • Sirolimus exhibits a pharmacokinetic profile comparable to other mTOR inhibitors.
  • The study provides a basis for further clinical trials evaluating SRL in cancer treatment.

Outlook:

  • Further clinical trials with larger patient cohorts are encouraged to evaluate SRL's role in targeted cancer therapy.
  • Investigating drug interactions, such as with grapefruit juice or ketoconazole, can optimize SRL dosing.
  • Sirolimus may represent a promising targeted therapeutic agent for various advanced cancers.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...